Daria G. Ulrikh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daria G. Ulrikh has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Petr V. Krivorotko
N.N. Petrov National Medical Research Oncology Center, Ministry of Health of Russia
12 shared publications - Tengiz T. Tabagua
N.N. Petrov National Medical Research Oncology Center, Ministry of Health of Russia
9 shared publications - Vladimir Fedorovich Semiglazov
N.N. Petrov National Medical Research Oncology Center, Ministry of Health of Russia
8 shared publications - Ya. Ig. Bondarchuk
N.N. Petrov Research Institute of Oncology, Ministry of Health of Russia
7 shared publications - Konstantin Yu. Zernov
N.N. Petrov National Medical Research Oncology Center, Ministry of Health of Russia
6 shared publications - Nikolay S. Amirov
N.N. Petrov Research Institute of Oncology, Ministry of Health of Russia
6 shared publications
Latest Publications
- Open Access
- 20 January 2026
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 21 (4) , 14-22
The impact of adjuvant radiotherapy on complications among who underwent delayed breast reconstruction
Background. Рostmastectomy radiation therapy (PMRT) is one of the causes of complications in patients with breast cancer after delayed breast reconstruction (DBR). Aim. To conduct a retrospective analysis of DBR outcomes and evaluate the impact of PMRT on the frequency and nature of complications. Materials and methods. Data from 178 patients with breast cancer who underwent DBR at N. N. Petrov National Medical Research Oncology Center, from 2015 to 2021 were included. In 87 patients, PMRT was administered to the soft tissues of the anterior chest wall and regional lymph nodes (group 1). Reconstruction with tissue expanders was performed in 66 (75.9 %), women while 1 (1.1 %) patient received a permanent implant. Six (6.9 %) patients underwent combined reconstruction using an expander with a thoraco-dorsal flap (TDF). In five (5.7 %) cases, a permanent implant was combined with TDF. Autologous reconstruction techniques were used in 10.3 % of cases (9 patients). Among the remaining 91 women PMRT was not performed (group 2). In this group, 69 (75.8 %) patients underwent reconstruction with tissue expanders, 2 (2.2 %) patients received permanent implants, 10 (11 %) patients had implants combined with TDF, and the combination of tissue expander with TDL was used in 2 (2.2 %) patients. Eight (8.8 %) patients underwent autologous reconstruction. Complications were assessed based on data from the medical information system “Vista” and telephone surveys and were determined as reconstructive failure (RF) and capsular contracture (CC) of Baker grades III–IV. Results. The mean follow-up duration was 48 months [14.5; 89.0] in the PMRT group and 63 months [38; 94] in the non-PMRT group. The overall complication rate was 27.5 % (49 cases), including reconstructive failures in 23 % (41 cases) and clinically significant СС (Baker III–IV) in 4.5 % (8 cases). RF occurred in 29.9 % of patients who received PMRT versus 16.5 % in those who did not (p = 0.03). The incidence of CC did not differ significantly: approximately 4.6 % in the PMRT group versus 4.4 % in the non-PMRT group (p = 0.95). Among patients who received PMRT after reconstruction with tissue expander RF were higher (33.3 %) compared to 14.5 % in non-irradiated patients (p = 0.01). Complications following autologous reconstruction occurred frequently regardless of PMRT status and probably were associated with the ability of surgery. Conclusion. Radiotherapy increases the risk of RF after DBR but was not associated with the risk of CC. Our data highlight the need to consider the impact of PMRT when planning DBR.
- 20 January 2026
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 21 (4) , 14-22
Open AccessThe impact of adjuvant radiotherapy on complications among who underwent delayed breast reconstruction
Background. Рostmastectomy radiation therapy (PMRT) is one of the causes of complications in patients with breast cancer after delayed breast reconstruction (DBR). Aim. To conduct a retrospective analysis of DBR outcomes and evaluate the impact of PMRT on the frequency and nature of complications. Materials and methods. Data from 178 patients with breast cancer who underwent DBR at N. N. Petrov National Medical Research Oncology Center, from 2015 to 2021 were included. In 87 patients, PMRT was administered to the soft tissues of the anterior chest wall and regional lymph nodes (group 1). Reconstruction with tissue expanders was performed in 66 (75.9 %), women while 1 (1.1 %) patient received a permanent implant. Six (6.9 %) patients underwent combined reconstruction using an expander with a thoraco-dorsal flap (TDF). In five (5.7 %) cases, a permanent implant was combined with TDF. Autologous reconstruction techniques were used in 10.3 % of cases (9 patients). Among the remaining 91 women PMRT was not performed (group 2). In this group, 69 (75.8 %) patients underwent reconstruction with tissue expanders, 2 (2.2 %) patients received permanent implants, 10 (11 %) patients had implants combined with TDF, and the combination of tissue expander with TDL was used in 2 (2.2 %) patients. Eight (8.8 %) patients underwent autologous reconstruction. Complications were assessed based on data from the medical information system “Vista” and telephone surveys and were determined as reconstructive failure (RF) and capsular contracture (CC) of Baker grades III–IV. Results. The mean follow-up duration was 48 months [14.5; 89.0] in the PMRT group and 63 months [38; 94] in the non-PMRT group. The overall complication rate was 27.5 % (49 cases), including reconstructive failures in 23 % (41 cases) and clinically significant СС (Baker III–IV) in 4.5 % (8 cases). RF occurred in 29.9 % of patients who received PMRT versus 16.5 % in those who did not (p = 0.03). The incidence of CC did not differ significantly: approximately 4.6 % in the PMRT group versus 4.4 % in the non-PMRT group (p = 0.95). Among patients who received PMRT after reconstruction with tissue expander RF were higher (33.3 %) compared to 14.5 % in non-irradiated patients (p = 0.01). Complications following autologous reconstruction occurred frequently regardless of PMRT status and probably were associated with the ability of surgery. Conclusion. Radiotherapy increases the risk of RF after DBR but was not associated with the risk of CC. Our data highlight the need to consider the impact of PMRT when planning DBR.
- Open Access
- 20 November 2025
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 24 (5) , 5-16
The paradigm shift, the definition of pregnancy-associated breast cancer is outdated
Background. Pregnancy-associated breast cancer (PABC) is diagnosed during pregnancy or within one year postpartum and is characterized by a more aggressive clinical course and poorer prognosis compared to breast cancer in non-pregnant patients. This is attributed to delayed diagnosis, distinct tumor biological features (such as HER2-positivity or triple-negative status), as well as differences in the tumor microenvironment during pregnancy and lactation. Objective : to determine the prognosis of breast cancer depending on the time to diagnosis (during pregnancy or in the early postpartum period). Material and Methods. The study included 56 patients diagnosed with pregnancy-associated breast cancer (PABC) who received treatment at N.N. Petrov National Medical Research Center of Oncology and V.A. Almazov National Medical Research Center (Russian Ministry of Health) between January 2016 and August 2024. Among them, 35 cases of breast cancer were diagnosed during pregnancy (PrBC), 21 patients were diagnosed in the postpartum period (PPBC). These patients were matched with two control groups, comprising 70 and 42 patients, respectively, based on age at diagnosis (±3 years), year of diagnosis (±2 years), clinical stage, and immunohistochemical (IHC) subtype. Results . The mean patient age was 34.9 years (range: 27–45 years). Most pregnant women sought medical attention at breast cancer stages II–III (28/35, 80 %), with regional lymph node (LN) involvement (20/35, 57.1 %). Among lactating patients, 71.4 % (15/21) presented at stages II–III, with LN metastasis observed in 71.4 % (15/21). In the PPBC group, 66.7 % (14/21) of patients had hormone receptor-positive tumors. The majority of PrBC cases (21/35, 60 %) were ERand PR-negative, with half of the patients exhibiting triple-negative breast cancer subtype (16/35, 45.7 %). The median follow-up duration was 50 months (range: 6 months to 8 years). Disease progression occurred in 22.9 % (8/35) of pregnancy-associated cases and 38.1 % (8/21) of lactationassociated cases. Three-year disease-free survival (DFS) rates were 73.1 % in the PrBC group versus 85.3 % in controls (p=0.014), and 51.1 % in the PPBC group versus 81.9 % in controls (p=0.032). Conclusion . The timing of breast cancer diagnosis (during pregnancy or in the early postpartum period) may serve as an independent prognostic factor for adverse outcomes. Our study demonstrated a statistically significant reduction in DFS rates in both PrBC (13.8 % decrease) and PPBC (30.8 % decrease) groups compared to the matched controls (p<0.05). Only separating pregnancy-associated breast cancer into PrBC and PPBC can improve our understanding of the tumor’s biological behavior during pregnancy, lactation, and involution.
- 20 November 2025
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 24 (5) , 5-16
Open AccessThe paradigm shift, the definition of pregnancy-associated breast cancer is outdated
Background. Pregnancy-associated breast cancer (PABC) is diagnosed during pregnancy or within one year postpartum and is characterized by a more aggressive clinical course and poorer prognosis compared to breast cancer in non-pregnant patients. This is attributed to delayed diagnosis, distinct tumor biological features (such as HER2-positivity or triple-negative status), as well as differences in the tumor microenvironment during pregnancy and lactation. Objective : to determine the prognosis of breast cancer depending on the time to diagnosis (during pregnancy or in the early postpartum period). Material and Methods. The study included 56 patients diagnosed with pregnancy-associated breast cancer (PABC) who received treatment at N.N. Petrov National Medical Research Center of Oncology and V.A. Almazov National Medical Research Center (Russian Ministry of Health) between January 2016 and August 2024. Among them, 35 cases of breast cancer were diagnosed during pregnancy (PrBC), 21 patients were diagnosed in the postpartum period (PPBC). These patients were matched with two control groups, comprising 70 and 42 patients, respectively, based on age at diagnosis (±3 years), year of diagnosis (±2 years), clinical stage, and immunohistochemical (IHC) subtype. Results . The mean patient age was 34.9 years (range: 27–45 years). Most pregnant women sought medical attention at breast cancer stages II–III (28/35, 80 %), with regional lymph node (LN) involvement (20/35, 57.1 %). Among lactating patients, 71.4 % (15/21) presented at stages II–III, with LN metastasis observed in 71.4 % (15/21). In the PPBC group, 66.7 % (14/21) of patients had hormone receptor-positive tumors. The majority of PrBC cases (21/35, 60 %) were ERand PR-negative, with half of the patients exhibiting triple-negative breast cancer subtype (16/35, 45.7 %). The median follow-up duration was 50 months (range: 6 months to 8 years). Disease progression occurred in 22.9 % (8/35) of pregnancy-associated cases and 38.1 % (8/21) of lactationassociated cases. Three-year disease-free survival (DFS) rates were 73.1 % in the PrBC group versus 85.3 % in controls (p=0.014), and 51.1 % in the PPBC group versus 81.9 % in controls (p=0.032). Conclusion . The timing of breast cancer diagnosis (during pregnancy or in the early postpartum period) may serve as an independent prognostic factor for adverse outcomes. Our study demonstrated a statistically significant reduction in DFS rates in both PrBC (13.8 % decrease) and PPBC (30.8 % decrease) groups compared to the matched controls (p<0.05). Only separating pregnancy-associated breast cancer into PrBC and PPBC can improve our understanding of the tumor’s biological behavior during pregnancy, lactation, and involution.
- Open Access
- 3 August 2025
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 21 (2) , 16-25
Breast cancer during pregnancy: an oncologist’s viewpoint
Background. Malignant neoplasms occur in 0.05–0.1 % of all pregnancies, breast cancer (BC) is the most common malignant neoplasm associated with pregnancy. The prognosis of this pathology remains a subject of debate due to conflicting research findings and requires a multidisciplinary approach to minimize risks for both mother and fetus. The prognosis of this pathology remains a subject of debate due to conflicting research findings and requires a multidisciplinary approach to minimize risks for both mother and fetus.Aim. Identification of problems in clinical and morphological diagnostics of pregnancy-associated BC to improve treatment outcomes.Materials and methods. This study included 35 patients over the age of 18 years with a diagnosis of breast cancer during pregnancy, who received treatment at the N.N. Petrov National Medical Research Oncology Center and the V.A. Almazov National Medical Research Center from May 2017 to March 2024.Results. The average age of patients was 35.34 ± 3.57 years. The diagnosis was established on average at 23 weeks of pregnancy, at stages II–III of the disease. 21 patients (60 %) were estrogen-receptor- and progesterone-receptornegative by the immunohistochemical subtype. Genetic mutations were detected in 30.3 % of cases. Pregnancy was terminated in 3 (8.8 %) patients. Systemic therapy during pregnancy was performed in 18 (51.4 %) patients, surgery – in 3 (8.6 %) patients, and 11 (31.4 %) women refused treatment during pregnancy and started it only after delivery. Progression of BC was detected in 8 (22.9 %) of cases. Locoregional recurrence was diagnosed in 1 (2.9 %) patient.Conclusion. The complexity of treatment and the growth of the population of patients diagnosed with pregnancyassociated BC confirm the need for analysis of individual cases, multicenter studies, and the creation of a common registry to determine clear algorithms for diagnosis and management of this pathology. For timely diagnosis of BC during pregnancy, it is necessary to conduct examinations of the mammary glands (ultrasound diagnostics) in early stages of women over 30 years of age. It is necessary to further study the division of the concepts of diagnosis of BC during pregnancy and BC during lactation (for at least 3 years after delivery) for a more accurate assessment of the prognosis of the disease and optimization of recommendations for the management of these patients.
- 3 August 2025
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 21 (2) , 16-25
Open AccessBreast cancer during pregnancy: an oncologist’s viewpoint
Background. Malignant neoplasms occur in 0.05–0.1 % of all pregnancies, breast cancer (BC) is the most common malignant neoplasm associated with pregnancy. The prognosis of this pathology remains a subject of debate due to conflicting research findings and requires a multidisciplinary approach to minimize risks for both mother and fetus. The prognosis of this pathology remains a subject of debate due to conflicting research findings and requires a multidisciplinary approach to minimize risks for both mother and fetus.Aim. Identification of problems in clinical and morphological diagnostics of pregnancy-associated BC to improve treatment outcomes.Materials and methods. This study included 35 patients over the age of 18 years with a diagnosis of breast cancer during pregnancy, who received treatment at the N.N. Petrov National Medical Research Oncology Center and the V.A. Almazov National Medical Research Center from May 2017 to March 2024.Results. The average age of patients was 35.34 ± 3.57 years. The diagnosis was established on average at 23 weeks of pregnancy, at stages II–III of the disease. 21 patients (60 %) were estrogen-receptor- and progesterone-receptornegative by the immunohistochemical subtype. Genetic mutations were detected in 30.3 % of cases. Pregnancy was terminated in 3 (8.8 %) patients. Systemic therapy during pregnancy was performed in 18 (51.4 %) patients, surgery – in 3 (8.6 %) patients, and 11 (31.4 %) women refused treatment during pregnancy and started it only after delivery. Progression of BC was detected in 8 (22.9 %) of cases. Locoregional recurrence was diagnosed in 1 (2.9 %) patient.Conclusion. The complexity of treatment and the growth of the population of patients diagnosed with pregnancyassociated BC confirm the need for analysis of individual cases, multicenter studies, and the creation of a common registry to determine clear algorithms for diagnosis and management of this pathology. For timely diagnosis of BC during pregnancy, it is necessary to conduct examinations of the mammary glands (ultrasound diagnostics) in early stages of women over 30 years of age. It is necessary to further study the division of the concepts of diagnosis of BC during pregnancy and BC during lactation (for at least 3 years after delivery) for a more accurate assessment of the prognosis of the disease and optimization of recommendations for the management of these patients.
- Open Access
- 8 May 2025
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 21 (1) , 44-55
A balance between breast reconstruction and amputation, Goldilock mastectomy
Background. Goldilocks mastectomy is an innovative surgical technique developed for patients with breast cancer who are looking for a balance between oncologically safe tumor removal and an optimal final aesthetic result.Aim. To perform an optimal type of reconstruction in overweight patients with serious comorbidities who have abandoned the standard options for restoring the shape of the breast by preserving a de-epidermized lower flap during mastectomy.Materials and methods. This study included 22 patients (31 Goldilocks mastectomy) aged 31 to 75 years diagnosed with breast cancer who received treatment from June 2023 to November 2024 at the N.N. Petrov Research Institute of Oncology. The average body mass index was 29.69 ± 3.92 kg/m2. Obesity was diagnosed in 86.4 % (19/22) of cases. All patients had 2 or 3 degrees of mammary gland ptosis.Results. In 59.1 % (13/22) of cases patients underwent unilateral Goldilocks mastectomies, in 40.9 % (9/22) – bilateral operations using this technique. In 16 patients (72.7 %) the nipple-areolar complex was preserved. The overall complication rate was 12.9 % (4/31). The patients noted that the final subjective perception of the treatment results exceeded the expectations of the performed surgical intervention.Conclusion. Breast reconstruction in overweight patients can be performed in various ways. Based on the experience of the N.N. Petrov Research Institute of Oncology and the results of this study, Goldilocks mastectomy is the best reconstruction option for patients with high body mass index or ptosis of the mammary glands, as well as concomitant diseases. This technique allows the surgeon to remove breast tissue within the anterior and posterior leaves of the superficial fascia, create additional volume using a de-epidermized flap, which preserves oncological safety and improves the aesthetic result.
- 8 May 2025
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 21 (1) , 44-55
Open AccessA balance between breast reconstruction and amputation, Goldilock mastectomy
Background. Goldilocks mastectomy is an innovative surgical technique developed for patients with breast cancer who are looking for a balance between oncologically safe tumor removal and an optimal final aesthetic result.Aim. To perform an optimal type of reconstruction in overweight patients with serious comorbidities who have abandoned the standard options for restoring the shape of the breast by preserving a de-epidermized lower flap during mastectomy.Materials and methods. This study included 22 patients (31 Goldilocks mastectomy) aged 31 to 75 years diagnosed with breast cancer who received treatment from June 2023 to November 2024 at the N.N. Petrov Research Institute of Oncology. The average body mass index was 29.69 ± 3.92 kg/m2. Obesity was diagnosed in 86.4 % (19/22) of cases. All patients had 2 or 3 degrees of mammary gland ptosis.Results. In 59.1 % (13/22) of cases patients underwent unilateral Goldilocks mastectomies, in 40.9 % (9/22) – bilateral operations using this technique. In 16 patients (72.7 %) the nipple-areolar complex was preserved. The overall complication rate was 12.9 % (4/31). The patients noted that the final subjective perception of the treatment results exceeded the expectations of the performed surgical intervention.Conclusion. Breast reconstruction in overweight patients can be performed in various ways. Based on the experience of the N.N. Petrov Research Institute of Oncology and the results of this study, Goldilocks mastectomy is the best reconstruction option for patients with high body mass index or ptosis of the mammary glands, as well as concomitant diseases. This technique allows the surgeon to remove breast tissue within the anterior and posterior leaves of the superficial fascia, create additional volume using a de-epidermized flap, which preserves oncological safety and improves the aesthetic result.
- Open Access
- 8 May 2025
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 21 (1) , 14-21
Comparative analysis of survival rates of pre- and postmenopausal patients with early breast cancer
Introduction. Breast cancer, which occurs in young women, is more often classified as a biologically aggressive subtype (HER2+ and triple negative) compared with postmenopausal patients. At the same time, it is important to know whether age, in itself, determines a less favorable outcome of the disease in young patients.Aim. To evaluate overall and recurrence-free survival rates in premenopausal and postmenopausal patients who underwent various levels of surgery and received neoadjuvant and adjuvant systemic therapy.Materials and methods. Of the 3,450 analyzed patients, the final analysis included 265 patients with breast cancer (clinical stage T1–3N0–1M0) who received treatment between 2011 and 2019, who were divided into 2 groups depending on age category, biological tumor subtype, types of neoadjuvant and adjuvant treatment.Results. Of 265 included patients, 162 (61.1 %) were premenopausal women, 103 (38.9 %) were postmenopausal women. The median follow-up was 5 years. The 5-year overall survival was 96.8 % (95 % confidence interval (CI) 92.6–98.7) in premenopausal patients and 95.1 % (95 % CI 88.5–97.9) in postmenopausal patients. The differences in overall survival estimated using the likelihood ratio test were not statistically significant (p = 0.927). The 5-year recurrencefree survival rate was 77.6 % (95 % CI 70.3–83.3) in premenopausal patients and 84.2 % (95 % CI 75.6–90.0) in postmenopausal patients. The differences in disease-free survival estimated using the likelihood ratio test were not statistically significant (p = 0.253).Conclusion. When comparing patients with early breast cancer, overall and relapse-free survival did not depend on menopausal status. It is necessary to conduct randomized trials to determine the effectiveness of drug therapy.
- 8 May 2025
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 21 (1) , 14-21
Open AccessComparative analysis of survival rates of pre- and postmenopausal patients with early breast cancer
Introduction. Breast cancer, which occurs in young women, is more often classified as a biologically aggressive subtype (HER2+ and triple negative) compared with postmenopausal patients. At the same time, it is important to know whether age, in itself, determines a less favorable outcome of the disease in young patients.Aim. To evaluate overall and recurrence-free survival rates in premenopausal and postmenopausal patients who underwent various levels of surgery and received neoadjuvant and adjuvant systemic therapy.Materials and methods. Of the 3,450 analyzed patients, the final analysis included 265 patients with breast cancer (clinical stage T1–3N0–1M0) who received treatment between 2011 and 2019, who were divided into 2 groups depending on age category, biological tumor subtype, types of neoadjuvant and adjuvant treatment.Results. Of 265 included patients, 162 (61.1 %) were premenopausal women, 103 (38.9 %) were postmenopausal women. The median follow-up was 5 years. The 5-year overall survival was 96.8 % (95 % confidence interval (CI) 92.6–98.7) in premenopausal patients and 95.1 % (95 % CI 88.5–97.9) in postmenopausal patients. The differences in overall survival estimated using the likelihood ratio test were not statistically significant (p = 0.927). The 5-year recurrencefree survival rate was 77.6 % (95 % CI 70.3–83.3) in premenopausal patients and 84.2 % (95 % CI 75.6–90.0) in postmenopausal patients. The differences in disease-free survival estimated using the likelihood ratio test were not statistically significant (p = 0.253).Conclusion. When comparing patients with early breast cancer, overall and relapse-free survival did not depend on menopausal status. It is necessary to conduct randomized trials to determine the effectiveness of drug therapy.
- Open Access
- 12 January 2025
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 23 (6) , 22-31
Impact of dose fractionation regimen of adjuvant radiotherapy on cosmetic outcomes after immediate breast reconstruction
Background. Evidence for the safety of using the hypofractionation (HF) regimen after immediate breast reconstruction (IBR) in patients with breast cancer is not well documented. the purpose of the study was a retrospective analysis of surgical treatment with IBR and postoperative radiation therapy (RT) in conventional fractionated (CF) and hypofractionated (HF) regimens in breast cancer patients. Material and Methods. a retrospective analysis of treatment outcomes was carried out in 219 breast cancer patients who underwent mastectomy with IBR using permanent implant or tissue expander. all patients received postoperative RT: 97 received CF RT (22–25 fractions of 2 Gy) and 122 HF RT (15–16 fractions of 2.66–2.7 Gy). Cosmetic complications were represented by reconstructive failure (RF). all patients underwent an analysis of the incidence of reconstructive failures (RF) or capsular contracture (CC) (Baker III–IV). Results. CF RT was performed in 97 women: 55 – after IBR using tissue expander and 42 using permanent implant. the median follow-up time was 61 months. Complications were observed in 37 women (35.1 %): RF in 22 cases (22.7 %) and CC in 12 (12.4 %) cases. the median time to RF was 8 months, CC – 48.5 months. after RT to the tissue expander, CC rate was 0 %, RF – 25.5 %. after RT to the implants, CC was revealed in 28.6 %, RF in 19 % cases. In patients who received HF RT, cosmetic complications were detected in 51 (41.8 %) of 122 patients. the median follow-up time was 34 months. RF was revealed in 22.1 % cases, the median time was 9 months. CC was observed in 24 women (19.7 %) with the median time of 27 months. after HF RT to the expander, CC was observed in 4.9 %, RF in 39 % of cases. After RT to the implant, CC was detected in 27.2 %, RF in 13.6 % of cases. no significant differences in the risk of complication between patients who received conventional or hypofractionated RT were found (р=0.19). after RT to the expander, no differences (р=0.18 and р=0.12). After RT to the implant, there were also no differences in the frequency of CC and RF (р=0.52 and р=0.42). Conclusion. There were no significant differences in the frequency of cosmetic complications after postoperative radiotherapy in conventional fractionation or moderate hypofractionation regimens.
- 12 January 2025
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 23 (6) , 22-31
Open AccessImpact of dose fractionation regimen of adjuvant radiotherapy on cosmetic outcomes after immediate breast reconstruction
Background. Evidence for the safety of using the hypofractionation (HF) regimen after immediate breast reconstruction (IBR) in patients with breast cancer is not well documented. the purpose of the study was a retrospective analysis of surgical treatment with IBR and postoperative radiation therapy (RT) in conventional fractionated (CF) and hypofractionated (HF) regimens in breast cancer patients. Material and Methods. a retrospective analysis of treatment outcomes was carried out in 219 breast cancer patients who underwent mastectomy with IBR using permanent implant or tissue expander. all patients received postoperative RT: 97 received CF RT (22–25 fractions of 2 Gy) and 122 HF RT (15–16 fractions of 2.66–2.7 Gy). Cosmetic complications were represented by reconstructive failure (RF). all patients underwent an analysis of the incidence of reconstructive failures (RF) or capsular contracture (CC) (Baker III–IV). Results. CF RT was performed in 97 women: 55 – after IBR using tissue expander and 42 using permanent implant. the median follow-up time was 61 months. Complications were observed in 37 women (35.1 %): RF in 22 cases (22.7 %) and CC in 12 (12.4 %) cases. the median time to RF was 8 months, CC – 48.5 months. after RT to the tissue expander, CC rate was 0 %, RF – 25.5 %. after RT to the implants, CC was revealed in 28.6 %, RF in 19 % cases. In patients who received HF RT, cosmetic complications were detected in 51 (41.8 %) of 122 patients. the median follow-up time was 34 months. RF was revealed in 22.1 % cases, the median time was 9 months. CC was observed in 24 women (19.7 %) with the median time of 27 months. after HF RT to the expander, CC was observed in 4.9 %, RF in 39 % of cases. After RT to the implant, CC was detected in 27.2 %, RF in 13.6 % of cases. no significant differences in the risk of complication between patients who received conventional or hypofractionated RT were found (р=0.19). after RT to the expander, no differences (р=0.18 and р=0.12). After RT to the implant, there were also no differences in the frequency of CC and RF (р=0.52 and р=0.42). Conclusion. There were no significant differences in the frequency of cosmetic complications after postoperative radiotherapy in conventional fractionation or moderate hypofractionation regimens.
- 20 December 2024
- Published by ECO-Vector LLC in HERALD of North-Western State Medical University named after I.I. Mechnikov
- Vol. 16 (4) , 74-85
Capsular contracture in the modern era of combined breast cancer treatment: a multidisciplinary perspective on incidence and risk factors
BACKGROUND: Implant-based breast reconstruction in contrast to autologous reconstruction often requires revision surgery and ultimately leads to reconstructive failure, especially in adjuvant radiation therapy. Capsular contracture remains the most common complication leading to unsatisfactory aesthetic results. To date, there is no therapeutic target for the direct treatment of capsular contracture, which emphasizes the importance of its prevention. AIM: To determine the incidence and risk factors of capsular contracture in the era of multidisciplinary breast cancer treatment using modern surgical and therapeutic approaches. MATERIALS AND METHODS: The following retrospective study included 416 patients after mastectomy with immediate or delayed implant-based breast reconstruction in combination with adjuvant radiation therapy. Features of the surgical intervention, neoadjuvant and/or adjuvant systemic therapy were analyzed to determine the association with the risk of developing capsular contracture. RESULTS: Capsular contracture during alloplastic reconstructive plastic surgery with adjuvant radiation therapy, according to the literature, is a common complication with a complex and multifactorial pathogenesis. Despite the low incidence of capsular contracture III–IV Baker scale in the present study (7.7%, 32/416), the majority of patients required revision surgery (90.6%, 29/32). There was no correlation between risk of capsular contracture depending on the systemic treatment (z 1.96). CONCLUSIONS: The development of capsular contracture was significantly influenced by nipple-sparing mastectomy (13.7%, 22/167; z = 3.25) and the choice of periareolar access during surgery (29.6%, 13/44; z 1.96). Immediate one-stage reconstructions are associated with a significant number of capsular contractures (15.2%, 24/158; z 1.96), which statistically significantly depend on the subpectoral location of the endoprosthesis (22.1%, 21/95; z = 2.79) and choice of textured implants (20.8%, 22/106; z = 2.02).
- 20 December 2024
- Published by ECO-Vector LLC in HERALD of North-Western State Medical University named after I.I. Mechnikov
- Vol. 16 (4) , 74-85
Capsular contracture in the modern era of combined breast cancer treatment: a multidisciplinary perspective on incidence and risk factors
BACKGROUND: Implant-based breast reconstruction in contrast to autologous reconstruction often requires revision surgery and ultimately leads to reconstructive failure, especially in adjuvant radiation therapy. Capsular contracture remains the most common complication leading to unsatisfactory aesthetic results. To date, there is no therapeutic target for the direct treatment of capsular contracture, which emphasizes the importance of its prevention. AIM: To determine the incidence and risk factors of capsular contracture in the era of multidisciplinary breast cancer treatment using modern surgical and therapeutic approaches. MATERIALS AND METHODS: The following retrospective study included 416 patients after mastectomy with immediate or delayed implant-based breast reconstruction in combination with adjuvant radiation therapy. Features of the surgical intervention, neoadjuvant and/or adjuvant systemic therapy were analyzed to determine the association with the risk of developing capsular contracture. RESULTS: Capsular contracture during alloplastic reconstructive plastic surgery with adjuvant radiation therapy, according to the literature, is a common complication with a complex and multifactorial pathogenesis. Despite the low incidence of capsular contracture III–IV Baker scale in the present study (7.7%, 32/416), the majority of patients required revision surgery (90.6%, 29/32). There was no correlation between risk of capsular contracture depending on the systemic treatment (z 1.96). CONCLUSIONS: The development of capsular contracture was significantly influenced by nipple-sparing mastectomy (13.7%, 22/167; z = 3.25) and the choice of periareolar access during surgery (29.6%, 13/44; z 1.96). Immediate one-stage reconstructions are associated with a significant number of capsular contractures (15.2%, 24/158; z 1.96), which statistically significantly depend on the subpectoral location of the endoprosthesis (22.1%, 21/95; z = 2.79) and choice of textured implants (20.8%, 22/106; z = 2.02).
- Open Access
- 8 November 2024
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 20 (3) , 16-21
Improving treatment outcomes for patients with HER2‑positive breast cancer using neoadjuvant double HER2 blockade
Background. Dual anti-HER2-targeted therapy in breast cancer (BC) significantly increased the rate of pathological complete response (pCR) compared to single blockade when added to chemotherapy. However, limited data exist on the long-term impact on survival of the additional increase in pCR.Aim. To improve recommendations regarding HER2-targeted agents and chemotherapy in the neoadjuvant treatment of BC.Materials and methods. N.N. Petrov National Medical Research Oncology Center, Ministry of Health of Russia took participation in some clinical trials of neoadjuvant treatment of HER2-positive breast cancer, including NeoSphere and NeoALTTO. In multicenter, open-label, phase 2 randomised NeoSphere trial, patients with locally advanced, inflammatory, or early-stage HER2-positive BC were randomly assigned to receive four neoadjuvant cycles of trastuzumab (8 mg/kg loading dose, followed by 6 mg/kg every 3 weeks) plus docetaxel (75 mg/m2 from every 3 weeks, increasing to 100 mg/m2 from cycle 2 if tolerated) (group A), pertuzumab (420 mg every 3 weeks) and trastuzumab plus docetaxel (group B), pertuzumab and trastuzumab (group C), or pertuzumab and docetaxel (group D). After surgery, patients received three cycles of FEC. Рatients in group C received four cycles of docetaxel prior to FEC, and trastuzumab 6 mg/kg every 3 weeks to complete 1 years treatment. In NeoALTTO trial from 455 patients 154 patients received lapatinib, 149 – trastuzumab, 152 – combination of lapatinib and trastuzumab.Results. Between 2007, and 2009, 417 patients were randomly assigned to group A (107 patients), group B (n = 107), group C (n = 107), or group D (n = 96). At clinical cutoff, 87 patients had disease progression or died. 5-year progressionfree survival rates were 81 % (95 % confidence interval (CI) 71–87) for group A, 86 % (95 % CI 72–91) for group B, 73 % for group C, and 73 % for group D (95 % CI 0.34–1.40). Disease-free survival rates were consistent with progressionfree survival rates and were 81 % (95 % CI 72–88) for group A, 84 % (95 % CI 72–91) for group B, 80 % (95 % CI 70–86) for group C, and 75 % (95 % CI 64–83) for group D. In NeoALTTO trial patients who achieved pCR had longer progressionfree survival (85 % (95 % CI 76–91)) compared with patients who did not achieve pCR (76 % (95 % CI 71–81)).Conclusion. High levels of progression-free survival and disease-free survival at 5–10-years follow-up show large and overlapping CI, but support the primary endpoint (pCR) and suggest that neoadjuvant pertuzumab is beneficial when combined with trastuzumab and docetaxel. Additionally, they suggest that pCR could be an early indicator of long-term outcome in early-stage HER2-positive BC.
- 8 November 2024
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 20 (3) , 16-21
Open AccessImproving treatment outcomes for patients with HER2‑positive breast cancer using neoadjuvant double HER2 blockade
Background. Dual anti-HER2-targeted therapy in breast cancer (BC) significantly increased the rate of pathological complete response (pCR) compared to single blockade when added to chemotherapy. However, limited data exist on the long-term impact on survival of the additional increase in pCR.Aim. To improve recommendations regarding HER2-targeted agents and chemotherapy in the neoadjuvant treatment of BC.Materials and methods. N.N. Petrov National Medical Research Oncology Center, Ministry of Health of Russia took participation in some clinical trials of neoadjuvant treatment of HER2-positive breast cancer, including NeoSphere and NeoALTTO. In multicenter, open-label, phase 2 randomised NeoSphere trial, patients with locally advanced, inflammatory, or early-stage HER2-positive BC were randomly assigned to receive four neoadjuvant cycles of trastuzumab (8 mg/kg loading dose, followed by 6 mg/kg every 3 weeks) plus docetaxel (75 mg/m2 from every 3 weeks, increasing to 100 mg/m2 from cycle 2 if tolerated) (group A), pertuzumab (420 mg every 3 weeks) and trastuzumab plus docetaxel (group B), pertuzumab and trastuzumab (group C), or pertuzumab and docetaxel (group D). After surgery, patients received three cycles of FEC. Рatients in group C received four cycles of docetaxel prior to FEC, and trastuzumab 6 mg/kg every 3 weeks to complete 1 years treatment. In NeoALTTO trial from 455 patients 154 patients received lapatinib, 149 – trastuzumab, 152 – combination of lapatinib and trastuzumab.Results. Between 2007, and 2009, 417 patients were randomly assigned to group A (107 patients), group B (n = 107), group C (n = 107), or group D (n = 96). At clinical cutoff, 87 patients had disease progression or died. 5-year progressionfree survival rates were 81 % (95 % confidence interval (CI) 71–87) for group A, 86 % (95 % CI 72–91) for group B, 73 % for group C, and 73 % for group D (95 % CI 0.34–1.40). Disease-free survival rates were consistent with progressionfree survival rates and were 81 % (95 % CI 72–88) for group A, 84 % (95 % CI 72–91) for group B, 80 % (95 % CI 70–86) for group C, and 75 % (95 % CI 64–83) for group D. In NeoALTTO trial patients who achieved pCR had longer progressionfree survival (85 % (95 % CI 76–91)) compared with patients who did not achieve pCR (76 % (95 % CI 71–81)).Conclusion. High levels of progression-free survival and disease-free survival at 5–10-years follow-up show large and overlapping CI, but support the primary endpoint (pCR) and suggest that neoadjuvant pertuzumab is beneficial when combined with trastuzumab and docetaxel. Additionally, they suggest that pCR could be an early indicator of long-term outcome in early-stage HER2-positive BC.
- Open Access
- 18 September 2024
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 7 (3) , 34-40
Dosimetric Comparison of Accelerated Partial Breast Irradiation Techniques: Multicatheter Interstitial Brachytherapy and Conformal External Beam Radiotherapy
Purpose: To compare dosimetric plans obtained in patients with breast cancer (BC) that underwent accelerated partial breast irradiation (APBI) by conformal external beam radiotherapy (EBRT) or interstitial high dose rate brachytherapy (HDRB).Material and methods: From 2017 to 2022 APBI was performed in 210 patients with stage I–II BC (рТ1N0M0–pT2N0M0). APBI was delivered to the tumor bed: in 99 cases — by EBRT, in another 111 patients — by HDRB. Leſt breast was irradiated in 101 women: in 51 women using HDRB, in 50 patients — by EBRT. Following dosimetric parameters were used for comparison of the dosimetric plans: Dmax – maximum dose in the organ at risk; Dmed – mean dose in the organ at risk (heart, leſt main coronary artery and its descending branch, ipsilateral lung, breast, skin and subcutaneous tissues).Results: When the tumor bed was irradiated by HDRB, in comparison with EBRT, Dmax for the skin and subcutaneous tissue decreases from 98.4 % to 68.7 %, р < 0.002. The use of HDRB made it possible to reduce the radiation load on the ipsilateral lung: Dmax decreased from 71.9 % to 42.7 % , р < 0.002; Dmed was 5.5 % for HDRB and 2.9 % for EBRT, р > 0.05. On the contrary EBRT associated with higher dose to the breast Dmed breast — 46 % in comparison with HDRB Dmed breast — 16.5 % , р < 0.002. Dose to the heart was higher with HDBT Dmax heart — 20.2 %, Dmed heart was 4.9 % than with EBRT Dmax heart — 14.4 %, Dmed heart — 0.8 %. Dose to the left coronary artery with HDRB Dmax — 6.5 % , Dmed — 3.9 % was higher than with EBRT Dmax — 3.3 % , Dmed — 1.3 % . Dose to the descending branch of the left coronary artery was higher with HDRB Dmax — 12.6 % , Dmed — 9.3 % than with EBRT Dmax — 8.9 % and Dmed — 3.4 % . But this differences were non-significant (р > 0.05).Conclusions. APBI by HDRB associated by significant reduction of the radiation dose to the ipsilateral breast lung, breast, skin and subcutaneous tissues.
- 18 September 2024
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 7 (3) , 34-40
Open AccessDosimetric Comparison of Accelerated Partial Breast Irradiation Techniques: Multicatheter Interstitial Brachytherapy and Conformal External Beam Radiotherapy
Purpose: To compare dosimetric plans obtained in patients with breast cancer (BC) that underwent accelerated partial breast irradiation (APBI) by conformal external beam radiotherapy (EBRT) or interstitial high dose rate brachytherapy (HDRB).Material and methods: From 2017 to 2022 APBI was performed in 210 patients with stage I–II BC (рТ1N0M0–pT2N0M0). APBI was delivered to the tumor bed: in 99 cases — by EBRT, in another 111 patients — by HDRB. Leſt breast was irradiated in 101 women: in 51 women using HDRB, in 50 patients — by EBRT. Following dosimetric parameters were used for comparison of the dosimetric plans: Dmax – maximum dose in the organ at risk; Dmed – mean dose in the organ at risk (heart, leſt main coronary artery and its descending branch, ipsilateral lung, breast, skin and subcutaneous tissues).Results: When the tumor bed was irradiated by HDRB, in comparison with EBRT, Dmax for the skin and subcutaneous tissue decreases from 98.4 % to 68.7 %, р < 0.002. The use of HDRB made it possible to reduce the radiation load on the ipsilateral lung: Dmax decreased from 71.9 % to 42.7 % , р < 0.002; Dmed was 5.5 % for HDRB and 2.9 % for EBRT, р > 0.05. On the contrary EBRT associated with higher dose to the breast Dmed breast — 46 % in comparison with HDRB Dmed breast — 16.5 % , р < 0.002. Dose to the heart was higher with HDBT Dmax heart — 20.2 %, Dmed heart was 4.9 % than with EBRT Dmax heart — 14.4 %, Dmed heart — 0.8 %. Dose to the left coronary artery with HDRB Dmax — 6.5 % , Dmed — 3.9 % was higher than with EBRT Dmax — 3.3 % , Dmed — 1.3 % . Dose to the descending branch of the left coronary artery was higher with HDRB Dmax — 12.6 % , Dmed — 9.3 % than with EBRT Dmax — 8.9 % and Dmed — 3.4 % . But this differences were non-significant (р > 0.05).Conclusions. APBI by HDRB associated by significant reduction of the radiation dose to the ipsilateral breast lung, breast, skin and subcutaneous tissues.
- Open Access
- 25 July 2024
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 20 (2) , 24-31
The impact of adjuvant radiotherapy for cosmetic results after immediate breast reconstruction based on the tissue expander and permanent implant
Background. One of the causes of complications in breast cancer patients after immediate breast reconstruction (IBR) is postmastectomy radiation therapy (PMRT).Aim. Retrospective analysis of the results of IBR, and evaluating the effect of PMRT on the frequency and type of complications.Materials and methods. Between 2015 and 2021, 798 patients underwent IBR with tissue expander or implant in N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia. PMRT was performed in 375 patients (group 1). The remaining 423 patients did not receive PMRT (group 2). Complications, including reconstructive failure (RF), Baker grade III/IV capsular contracture (CC), were recorded and analyzed.Results. Finally, cosmetic result analyzed in 521 patients. In 281 patients of PMRT group (group 1) IBR with expander or implant were performed in 144 and 137 cases, respectively. In the 240 patients without PMRT (group 2), IBR with expander was performed in 81 patients, with implant – in 159 cases. Pooled analysis revealed that overall rate of complications in the PMRT group was 33.8 % (in 95 of 281 patients), in non-irradiation patients – 22.9 % (in 55 of 240 patients), p 0.01. In group 1, RF were recorded in 67 (23.8 %) patients, in group 2 – in 44 (18.3 %) patients, p 0.05. CC in group 1 were detected in 28 (10 %) patients, in group 2 in 11 (4.6 %) patients, p 0.05. In patients with permanent implants RF were detected in 21 (14.6 %) of irradiation patients and in 22 (13.8 %) non-irradiation patients (p 0.2). On the contrary, CC were mentioned in 22 (16.1 %) of irradiated patient and in 8 (5 %) patients that didn’t receive PMRT, p 0.005. After reconstruction with expander RF were diagnosed in 46 (31.9 %) patients after PMRT and in 22 (27.2 %) non-irradiation patients, p 0.2. CC were observed in 6 (4.2 %) patients from PMRT group and in 3 (3.7 %) patients treated without PMRT, p 0.2.Conclusion. PMRT in patients after IBR with simultaneous installation of a permanent implant is characterized by a decrease in the incidence of RF, but an increase in the incidence of CC.
- 25 July 2024
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 20 (2) , 24-31
Open AccessThe impact of adjuvant radiotherapy for cosmetic results after immediate breast reconstruction based on the tissue expander and permanent implant
Background. One of the causes of complications in breast cancer patients after immediate breast reconstruction (IBR) is postmastectomy radiation therapy (PMRT).Aim. Retrospective analysis of the results of IBR, and evaluating the effect of PMRT on the frequency and type of complications.Materials and methods. Between 2015 and 2021, 798 patients underwent IBR with tissue expander or implant in N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia. PMRT was performed in 375 patients (group 1). The remaining 423 patients did not receive PMRT (group 2). Complications, including reconstructive failure (RF), Baker grade III/IV capsular contracture (CC), were recorded and analyzed.Results. Finally, cosmetic result analyzed in 521 patients. In 281 patients of PMRT group (group 1) IBR with expander or implant were performed in 144 and 137 cases, respectively. In the 240 patients without PMRT (group 2), IBR with expander was performed in 81 patients, with implant – in 159 cases. Pooled analysis revealed that overall rate of complications in the PMRT group was 33.8 % (in 95 of 281 patients), in non-irradiation patients – 22.9 % (in 55 of 240 patients), p 0.01. In group 1, RF were recorded in 67 (23.8 %) patients, in group 2 – in 44 (18.3 %) patients, p 0.05. CC in group 1 were detected in 28 (10 %) patients, in group 2 in 11 (4.6 %) patients, p 0.05. In patients with permanent implants RF were detected in 21 (14.6 %) of irradiation patients and in 22 (13.8 %) non-irradiation patients (p 0.2). On the contrary, CC were mentioned in 22 (16.1 %) of irradiated patient and in 8 (5 %) patients that didn’t receive PMRT, p 0.005. After reconstruction with expander RF were diagnosed in 46 (31.9 %) patients after PMRT and in 22 (27.2 %) non-irradiation patients, p 0.2. CC were observed in 6 (4.2 %) patients from PMRT group and in 3 (3.7 %) patients treated without PMRT, p 0.2.Conclusion. PMRT in patients after IBR with simultaneous installation of a permanent implant is characterized by a decrease in the incidence of RF, but an increase in the incidence of CC.